The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
![](https://www.greenhill.com/sites/default/files/uk-japan.png)
Kyowa Kirin International’s established medicines business
![Germany Germany flag](https://www.greenhill.com/sites/default/files/germany.gif)
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company
![Japan Japan flag](https://www.greenhill.com/sites/default/files/japan.gif)
Japan Medical Dynamic Marketing
![Japan Japan flag](https://www.greenhill.com/sites/default/files/japan.gif)
Advising Mitsui Chemicals, one of the largest Japanese chemical companies, on the acquisition of a 30% stake in Japan Medical Dynamic Marketing, a leading orthopedic medical device manufacturer in Japan, held by NGK SPARK PLUG
![Spain Spain flag](https://www.greenhill.com/sites/default/files/spain.gif)
Deltalab
![Thailand Thailand flag](https://www.greenhill.com/sites/default/files/Thailand_flag_60839.gif)
Advising Deltalab, a leading Spanish laboratory solutions provider with dedicated manufacturing capacity, on the sale of the company to SCG Packaging Public Company Limited, the largest integrated packaging and paper company in Southeast Asia
![Denmark Denmark flag](https://www.greenhill.com/sites/default/files/denmark_flag%5B1%5D.gif)
Global collaboration agreement with Genmab A/S
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised AbbVie, Inc, an NYSE-listed global biopharmaceutical company, on a broad collaboration with Genmab A/S, a leading Danish-listed biotechnology company, to jointly develop and commercialise three next-generation bispecific antibody programs
![Saudi Arabia Saudi Arabia Flag](https://www.greenhill.com/sites/default/files/saudiarabia.gif)
Equity stake in Bupa Arabia
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advising Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia, the largest health insurance provider in the Kingdom of Saudi Arabia
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Asia and US rights to Physiogel
![South Korea Korea flag](https://www.greenhill.com/sites/default/files/Korea.jpg)
Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the rights to Physiogel Asia and the US to Korea-based LG Household & Health Care Ltd
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Assets owned by GlaxoSmithKline plc
![](https://www.greenhill.com/sites/default/files/uk_india_flags.png)
Advised GlaxoSmithKline plc, the UK listed international pharmaceutical and consumer healthcare company, on the divestment of Horlicks and other consumer healthcare nutrition brands to Unilever plc, and on the merger of GSK Consumer Healthcare Limited with Hindustan Unilever Limited
![Japan Japan flag](https://www.greenhill.com/sites/default/files/japan.gif)
Long-term lithium hydroxide offtake agreement with Mitsui & Co.
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Advised Kidman Resources Limited, an ASX-listed hard rock lithium mining company with a 50% interest in the West Australian Mt. Holland lithium project, on a lithium hydroxide offtake agreement with Mitsui & Co., a leading global marketing and trading conglomerate based in Japan. The agreement is for an initial term of two years, plus two 2-year term extension options
![](https://www.greenhill.com/sites/default/files/australia-indonesia-flag.png)
Martabe gold and silver mine
![](https://www.greenhill.com/sites/default/files/australia-indonesia-flag.png)
Advised EMR Capital, a specialist resources private equity manager, on the sale of the Martabe gold and silver mine to United Tractors
![South Africa/UK U.K., South Africa flags](https://www.greenhill.com/sites/default/files/safrica-uk.gif)
Lonmin
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advising Lonmin PLC, a major fully integrated producer of Platinum Group Metals, on the amendment of its debt facilities to support the review and implementation of its strategic options
![Germany Germany flag](https://www.greenhill.com/sites/default/files/germany.gif)
MorphoSys AG
![China China flag](https://www.greenhill.com/sites/default/files/china.gif)
Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab
![UK/Ireland U.K., Ireland flags](https://www.greenhill.com/sites/default/files/uk-ireland_35558.gif)
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
![India India flag](https://www.greenhill.com/sites/default/files/india.gif)
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
![India India flag](https://www.greenhill.com/sites/default/files/india.gif)
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.
![India India flag](https://www.greenhill.com/sites/default/files/india.gif)
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
![India India flag](https://www.greenhill.com/sites/default/files/india.gif)
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories
![South Africa/UK U.K., South Africa flags](https://www.greenhill.com/sites/default/files/safrica-uk.gif)
Lonmin Plc
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised Lonmin Plc on its c.$777mm recapitalization consisting of c.$370mm of bank facilities at the Plc and in South Africa from the Company’s ten lending banks and a fully underwritten Rights Issue of c.$407mm.
![Ireland Ireland flag](https://www.greenhill.com/sites/default/files/ireland.gif)
Allergan Generics
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
![Sweden Sweden flag](https://www.greenhill.com/sites/default/files/sweden.gif)
Unfors Raysafe AB
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised the Sixth Swedish National Pension Fund on the sale of Unfors Raysafe AB, a provider of easy-to-use products that help to reduce unnecessary radiation exposure, to Fluke Biomedical Corp., a subsidiary of Danaher Corp. that manufactures biomedical test and simulation products
![South Africa/UK U.K., South Africa flags](https://www.greenhill.com/sites/default/files/safrica-uk.gif)
Lonmin plc
Advised Lonmin plc, the world’s third largest primary producer of Platinum Group Metals, on a comprehensive refinancing of its balance sheet, including an underwritten ~$817mm rights issue and amendments to its existing ~$929mm debt facilities
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
Taro Pharmaceutical Industries
![India India flag](https://www.greenhill.com/sites/default/files/india.gif)
Advised Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of a majority interest in Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company
![Sweden Sweden flag](https://www.greenhill.com/sites/default/files/sweden.gif)
Biotage (Biosystems division)
![Netherlands Netherlands flag](https://www.greenhill.com/sites/default/files/niederland.gif)
Advised Biotage AB (OMX: BIOT), a global biotechnology company, on its strategic review resulting in the disposal of its Biosystems division which offers systems for genetic analysis mainly for use in clinical research
![South Africa/UK U.K., South Africa flags](https://www.greenhill.com/sites/default/files/safrica-uk.gif)
Lonmin plc
![Switzerland Switzerland flag](https://www.greenhill.com/sites/default/files/switzerland.gif)
Advised Lonmin plc, a major producer of Platinum Group Metals, regarding an unsolicited pre-conditional offer for the company by Xstrata plc, a global diversified mining company
![USA/Canada U.S.A., Canada flags](https://www.greenhill.com/sites/default/files/usa_canada.gif)
IPSCO Inc.
![Sweden Sweden flag](https://www.greenhill.com/sites/default/files/sweden.gif)
Acted as lead financial advisor to SSAB Svenskt Stål AB on its acquisition of IPSCO Inc., a leading Canadian producer of energy tubulars and steel plate in North America with an annual steel making capacity of 4.3 million tons